Your browser doesn't support javascript.
loading
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein
Hideki Tani; Long Tan; Miyuki Kimura; Yoshihiro Yoshida; Hiroshi Yamada; Shuetsu Fukushi; Masayuki Saijo; Hitoshi Kawasuji; Akitoshi Ueno; Yuki Miyajima; Yasutaka Fukui; Ippei Sakamaki; Yoshihiro Yamamoto; Yoshitomo Morinaga.
Afiliación
  • Hideki Tani; Toyama Institute of Health
  • Long Tan; University of Toyama
  • Miyuki Kimura; University of Toyama
  • Yoshihiro Yoshida; University of Toyama
  • Hiroshi Yamada; University of Toyama
  • Shuetsu Fukushi; National Institute of Infectious Diseases
  • Masayuki Saijo; National Institute of Infectious Diseases, Tokyo, Japan.
  • Hitoshi Kawasuji; Toyama University Graduate School of Medicine and Pharmaceutical Sciences
  • Akitoshi Ueno; Toyama University Graduate School of Medicine and Pharmaceutical Sciences
  • Yuki Miyajima; Toyama University Graduate School of Medicine and Pharmaceutical Sciences
  • Yasutaka Fukui; University of Toyama
  • Ippei Sakamaki; Toyama University Graduate School of Medicine and Pharmaceutical Sciences
  • Yoshihiro Yamamoto; Toyama University Graduate School of Medicine and Pharmaceutical Sciences
  • Yoshitomo Morinaga; Nagasaki University
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-262295
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an immunofluorescence assay (IFA). The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2.
Licencia
cc_no
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2020 Tipo del documento: Preprint